empty
 
 
pt
Pesquisar
Suporte
Abertura instanânea da conta
Plataforma de negociação
Depósito/Retirada
Pesquisar
Para Iniciantes Para Traders Para Parceiros Relaxe Sobre a InstaSpot
pt
For Traders
Charts
#ALNY

#ALNY (Alnylam Pharmaceuticals Inc.). Taxa de câmbio e gráficos online.

#ACB Voltar à lista de instrumentos #AMGN

Conversor de moedas

Alnylam Pharmaceuticals Inc.
240.1 USD
09 Jan 2025 18:32
Mudança de preço (% chg)
$0
(0%)
Fechamento anterior
Fechamento anterior

Preço de fechamento, no dia anterior.
$240.1
Abrir
Abrir

Preço de abertura.
$234.37
Máximo do dia
Máximo do dia

O preço mais alto do último dia de negociação.
$240.1
Mínimo do dia
Mínimo do dia

O preço mais baixo do último dia de negociação
$240.1
Alta de 52-semanas
Alta de 52-semanas

Faixa de preço alta nas últimas 52 semanas
$240.1
Baixa de 52-semana
Baixa de 52-semana

Faixa de preço baixa nas últimas 52 semanas
$234
Baixar arquivo
Buy
240.1
Sell
240.1
Open the chart in full screen view
Buy
240.1
Sell
240.1
Baixar arquivo
Open the chart in full screen view

Alnylam Pharmaceuticals Inc. About company

Alnylam Pharmaceuticals Inc. is an American biopharmaceutical company, founded in 2002. The firm is mainly involved in the research and development of drugs for treating genetic disorders.

In 2016, Alnylam Pharmaceuticals Inc. was added to the Forbes list of the world’s 100 most innovative growth companies.

This year, the market capitalization of Alnylam Pharmaceuticals Inc. totals $17.65 billion. In 2021, it raised revenue of $844.29 million. In the first six months of 2022, the company earned as much as $224.82 million.

Alnylam Pharmaceuticals Inc.’s shares and factors shaping their value

The company has been listed on the NASDAQ exchange since 2004 under the ALNY ticker. Its share value currently totals $200-205. Over the past 12 months, ALNY has fluctuated in the range of $117 to $236.

When trading the firm’s stock, you should pay attention to the following factors:

  • The company has a heavy dependence on the state of the healthcare sector as a whole. Thus, new COVID outbreaks have a negative influence on its revenue growth;
  • The company occasionally introduces new drugs to the market, conducting clinical and laboratory trials and publishing the results beforehand;
  • Constantly growing revenues are the firm’s advantage;
  • Enough own funds to finance projects without the need to additionally issue securities.

Não pode falar agora?
Faça sua pergunta no chat.